Context-Dependent Effects of PARP Inhibitors on Breast Cancer Bone Metastasis
PARP 抑制剂对乳腺癌骨转移的背景依赖性影响
基本信息
- 批准号:10551902
- 负责人:
- 金额:$ 36.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-10 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntineoplastic AgentsAttenuatedBRCA mutationsBinding ProteinsBiochemicalBone DiseasesBone PainBone ResorptionBreast Cancer therapyCancer EtiologyCell DeathCellsChIP-seqChromatinClinicalClinical TrialsCollaborationsCommunitiesDNA BindingDNA RepairDrug resistanceEnvironmentFDA approvedFamily memberGene Expression RegulationGeneticGenetic TranscriptionGenetic studyGenomicsGoalsHypercalcemiaIn VitroInvestigationKnockout MiceLifeMalignant Bone NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMetastatic Neoplasm to the BoneMicroRNAsMolecularMolecular TargetMusMutagenesisNatureNeoplasm MetastasisOsteoclastsPathological fracturePatientsPharmaceutical PreparationsPharmacology StudyPlayPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) PolymerasesPrimary NeoplasmProliferatingProteinsProteomicsRegulationResistanceRoleSchemeSeriesSkeletonTNFSF11 geneTestingTherapeuticTimeadvanced breast canceranalogbisphosphonatebonecancer cellcancer complicationcancer therapycandidate identificationcell typechemical geneticsclinical developmentclinically relevantdesigngain of functiongenetic approachin vivoindividualized medicineinhibitorinhibitor therapyinnovationinsightknock-downloss of functionmalignant breast neoplasmmortalityneoplastic cellnovelosteoclastogenesisoverexpressionpalliativepersonalized medicinepharmacologicskeletalspinal cord compressiontooltranscriptome sequencingtumortumor growth
项目摘要
Bone metastasis is a frequent, debilitating and essentially incurable cancer complication. More than 70% of
patients with advanced breast cancer have metastatic bone disease, leading to severe bone pain, pathological
fracture, life-threatening hypercalcemia, spinal cord compression, limited mobility and increased mortality.
During bone metastasis, cancer cells and osteoclasts form a vicious cycle so that cancer cells promote
osteoclast differentiation and osteoclasts in turn facilitate cancer cell seeding and proliferation in the skeletal
environment. Nonetheless, the current understanding of the intricate mechanisms underlying this malicious
cycle is still limited, and the existing osteoclast inhibitor drugs confer no survival benefit. Our overarching goal
is to discover new and better treatment for cancer bone metastasis that simultaneously suppresses both
cancer cell and osteoclast. In December 2014, an inhibitor of Poly (ADP-ribose) polymerase (PARP), Olaparib,
was approved by the FDA for treating elapsed BRCA-defective ovarian cancer. Since then, two more PARP
inhibitors have also received FDA approval. Several PARP1/2 dual inhibitors are also currently in clinical trials
as breast cancer therapy. Despite these clinical efforts on PARP inhibitors in cancer treatment, little is known
about the roles of PARPs in metastasis. Moreover, it is unclear whether and how different PARP family
members display distinct functions. In our preliminary studies, we have found that PARP2 loss, but not PARP1
loss, promotes bone metastasis by acting in both osteoclast and tumor cell to enhance osteoclastogenesis;
olaparib treatment exacerbates bone metastasis in a manner that is dependent on modifiers such as BRCA
status and drug resistance. We hypothesize that PARP2 is a powerful dual suppressor of bone metastasis by
regulating key targets in osteoclast and tumor cell to synergistically impede breast cancer malignancy. Here we
propose to perform a series of comprehensive analyses to test this hypothesis, combining genetic and
pharmacological, gain- and loss-of-function, in vitro and in vivo strategies. In Aim 1, we will determine how
PARPs in osteoclast regulate bone metastasis. In Aim 2, we will determine how PARPs in cancer cell regulate
bone metastasis. In Aim 3, we will elucidate the molecular and biochemical mechanisms for PARP regulation
of bone metastasis by identifying and functionally characterizing key PARP targets. This investigation is highly
significant and clinically relevant because it will identify PARP2 as a novel dual suppressor of breast cancer
bone metastasis, uncover potential deleterious yet context-dependent effects of current PARP1/2 dual inhibitor
cancer drugs to exacerbate skeletal metastasis, reveal important functional distinctions between PARP2 and
PARP1, suggest PARP1-specific inhibitors as possibly safer options, highlight the exciting therapeutic potential
of PARP2 activation to mitigate breast cancer bone metastasis, and provide crucial insights for personalized
medicine and tailored treatment to better design and utilize PARP inhibitors as cancer drugs.
骨转移是一种常见的、使人虚弱的、基本上无法治愈的癌症并发症。超过70%的
晚期乳腺癌患者有转移性骨病,导致严重骨痛、病理改变。
骨折、危及生命的高钙血症、脊髓受压、活动受限和死亡率增加。
在骨转移过程中,癌细胞和破骨细胞形成恶性循环,癌细胞促进
破骨细胞分化和破骨细胞反过来促进癌细胞在骨骼中的种植和增殖
环境。尽管如此,目前对这种恶意行为背后复杂机制的理解
周期仍然有限,现有的破骨细胞抑制剂药物对生存没有好处。我们的首要目标
是发现同时抑制两者的癌症骨转移的新的更好的治疗方法
癌细胞和破骨细胞。2014年12月,多聚(ADP-核糖)聚合酶(PARP)抑制剂奥拉帕利,
被FDA批准用于治疗晚期BRCA缺陷型卵巢癌。从那时起,又有两个PARP
抑制剂也获得了FDA的批准。几种PARP1/2双重抑制剂目前也在进行临床试验
作为乳腺癌的治疗方法。尽管临床上对PARP抑制剂在癌症治疗方面做出了这些努力,但人们对此知之甚少
关于PARPS在肿瘤转移中的作用。此外,目前还不清楚PARP家族是否以及如何不同
成员发挥着不同的功能。在我们的初步研究中,我们发现PARP2丢失,但PARP1没有
丢失,通过作用于破骨细胞和肿瘤细胞来促进破骨细胞的生成,从而促进骨转移;
奥拉帕利治疗以一种依赖于BRCA等修饰剂的方式加剧骨转移
状态和抗药性。我们假设PARP2是一种强大的骨转移双重抑制因子,它通过
调节破骨细胞和肿瘤细胞中的关键靶点以协同抑制乳腺癌的恶性。在这里我们
建议进行一系列全面的分析来检验这一假设,结合遗传和
药理、功能得失、体外和体内策略。在目标1中,我们将确定如何
破骨细胞中的PARPS调控骨转移。在目标2中,我们将确定癌细胞中PARP是如何调节的
骨转移。在目标3中,我们将阐明PARP调节的分子和生化机制。
通过识别和确定关键的PARP靶点来研究骨转移。这项调查是高度
具有重要意义和临床意义,因为它将确定PARP2是一种新的乳腺癌双重抑制因子
骨转移,揭示当前PARP1/2双重抑制剂的潜在有害但上下文相关的影响
癌症药物加剧骨转移,揭示PARP2和PARP2之间重要的功能差异
PARP1,建议PARP1特异性抑制剂可能是更安全的选择,突出了令人兴奋的治疗潜力
PARP2激活以减轻乳腺癌骨转移,并为个性化研究提供关键见解
药物和量身定做的治疗,以更好地设计和利用PARP抑制剂作为癌症药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM Lee KRAUS其他文献
WILLIAM Lee KRAUS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM Lee KRAUS', 18)}}的其他基金
Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology
转录因子 ADP-核糖基化在乳腺癌生物学中的作用
- 批准号:
10593900 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology
转录因子 ADP-核糖基化在乳腺癌生物学中的作用
- 批准号:
10374911 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology
转录因子 ADP-核糖基化在乳腺癌生物学中的作用
- 批准号:
10209984 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
Context-Dependent Effects of PARP Inhibitors on Breast Cancer Bone Metastasis
PARP 抑制剂对乳腺癌骨转移的背景依赖性影响
- 批准号:
9987293 - 财政年份:2018
- 资助金额:
$ 36.32万 - 项目类别:
Context-Dependent Effects of PARP Inhibitors on Breast Cancer Bone Metastasis
PARP 抑制剂对乳腺癌骨转移的背景依赖性影响
- 批准号:
9762058 - 财政年份:2018
- 资助金额:
$ 36.32万 - 项目类别:
Molecular and Genomic Mechanisms in the Biology of Pregnancy and Parturition
妊娠和分娩生物学中的分子和基因组机制
- 批准号:
9208678 - 财政年份:2016
- 资助金额:
$ 36.32万 - 项目类别:
Estrogen Signaling and Estrogen Receptor Alpha Acetylation in the Pregnant Myometrium
妊娠子宫肌层中的雌激素信号传导和雌激素受体α乙酰化
- 批准号:
10063453 - 财政年份:2016
- 资助金额:
$ 36.32万 - 项目类别:
Defining Gene Expression Programs in Cervical Ripening: Roles for Non-Coding RNAs
定义宫颈成熟中的基因表达程序:非编码 RNA 的作用
- 批准号:
8720038 - 财政年份:2013
- 资助金额:
$ 36.32万 - 项目类别:
Defining Gene Expression Programs in Cervical Ripening: Roles for Non-Coding RNAs
定义宫颈成熟中的基因表达程序:非编码 RNA 的作用
- 批准号:
8575168 - 财政年份:2013
- 资助金额:
$ 36.32万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 36.32万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 36.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 36.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 36.32万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 36.32万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 36.32万 - 项目类别: